SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) today announced that it is
offering to sell 7,000,000 shares of its common stock in an
underwritten public offering. In connection with this
offering, Neurocrine will also grant to the underwriters a 30-day
option to purchase up to an additional 1,050,000 shares of common
stock. Jefferies LLC and J.P. Morgan Securities LLC are acting as
joint book-running managers for this offering. The offering
is subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed or as
to the actual size or terms of the offering.
The securities described above are being offered by Neurocrine
pursuant to a shelf registration statement previously filed with
the Securities and Exchange Commission (the "SEC") on
February 25, 2014, which has become
effective by rule of the SEC. A preliminary prospectus
supplement and accompanying prospectus relating to the offering
have been filed with the SEC and are available on the
SEC's website at http://www.sec.gov. Copies of the preliminary
prospectus supplement and the accompanying prospectus relating to
these securities may also be obtained from Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 12th Floor, New York, NY
10022, or by telephone at 877-547-6340, or by email at
Prospectus_Department@Jefferies.com, or from J.P. Morgan Securities
LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, or by
telephone at 866-803-9204.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. is a clinical stage drug discovery
company primarily focused on neurological and endocrine based
diseases and disorders. Neurocrine discovers and develops
innovative pharmaceuticals, in diseases with high unmet medical
needs or where the existing drug classes are inadequate, through a
disciplined yet entrepreneurial process. Utilizing a portfolio
approach to drug discovery, Neurocrine has multiple small molecule
drug candidates at various stages of pharmaceutical development.
Neurocrine's two lead late stage clinical programs are elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc., and a wholly owned vesicular
monoamine transporter 2 ("VMAT2") inhibitor for the treatment of
movement disorders. Neurocrine intends to maintain certain
commercial rights to its VMAT2 inhibitor for evolution into a
fully-integrated pharmaceutical company.
In addition to historical facts, this press release contains
forward-looking statements that involve a number of risks and
uncertainties such as those, among others, relating to Neurocrine's
expectations regarding the completion, timing and size of its
proposed public offering. Among the factors that could
cause actual results to differ materially from those indicated in
the forward-looking statements are risks and uncertainties
associated with market conditions and the satisfaction of customary
closing conditions related to the proposed offering, as well as
risks and uncertainties associated with Neurocrine's business and
finances in general, and the other risks described in Neurocrine's
annual report on Form 10-K for the year ended December 31, 2013. Neurocrine undertakes no
obligation to update the statements contained in this press release
after the date hereof.
SOURCE Neurocrine Biosciences, Inc.